Vical slashes staff after culling phase II antifungal

US biotech Vical is planning another round of job cuts after deciding to abandon its antifungal drug VL-2397, its last remaining clinical-stage asset. The San Diego company only started the phase II trial of VL-2397 last year, but says a slow uptake of patients into the trial, coupled with a need to conserve cash, is behind the decision.
Read more...

;